Tesofensine vs semaglutide verdict
On tesofensine vs semaglutide, one fact decides most of the choice: only semaglutide exists as a medicine a clinician can review you for. FDA first approved semaglutide in 2017 and approved it for chronic weight management, as Wegovy, in 2021 (Drugs@FDA). Tesofensine has never been approved for any use.
Harbor's semaglutide program pairs the weekly shot with a board-certified physician's review before anything ships, and it puts medication, clinician care and check-ins in one flat price with no insurance required. The semaglutide in that program is compounded, and compounded semaglutide is not FDA approved.
Tesofensine's appeal is easy to see. It is a tablet, and a 2008 trial reported mean weight loss of up to 10.6% beyond diet and placebo. That trial was a phase 2 study of 203 people over 24 weeks, and its authors wrote that the findings needed confirmation in phase 3.
Interesting, and unfinished.
Tesofensine vs semaglutide shots side by side
Tesofensine and semaglutide shots differ on five counts: what each one is, how it works, how much human evidence stands behind it, where it stands with FDA and how it reaches a patient.
What tesofensine is
Tesofensine, also written NS 2330, is an oral drug taken once a day in its trials. Its earliest registered trials were in brain conditions. Phase 2 trials in Parkinson's disease and Alzheimer's disease began in 2003, and the first registered obesity trial followed in 2006.
It is not a GLP-1 medicine. Its developer, the Danish company Saniona, describes it as a triple monoamine reuptake inhibitor supplied as tablets.
How each one works
Semaglutide copies a gut hormone. On the Wegovy label it is a GLP-1 receptor agonist that binds to and activates the GLP-1 receptor, and the label calls GLP-1 a physiological regulator of appetite and caloric intake (Wegovy prescribing information). In the plainer words of the semaglutide program page, it "mimics a natural hormone that regulates hunger and satiety."
Tesofensine acts on brain chemistry instead. The phase 2 investigators describe it as an inhibitor of the presynaptic uptake of noradrenaline, dopamine and serotonin, three chemical messengers (Lancet, 2008). In a two-week study of 32 men it raised ratings of satiety and fullness, and the authors wrote that the mechanisms behind its weight loss in humans were unresolved (Int J Obes, 2010).
Two different systems, and only one is described on an FDA label.
What the trial evidence shows
Tesofensine's published weight evidence in obesity rests on one mid-stage trial. In 2008, a phase 2 study at five Danish obesity centers assigned 203 adults with a BMI of 30 to 40 to one of three study doses or placebo, each with a reduced-calorie diet, for 24 weeks. Mean weight loss ran 4.5%, 9.2% and 10.6% greater than diet and placebo at 0.25 mg, 0.5 mg and 1.0 mg a day, and diet with placebo produced 2.0% (Lancet, 2008).
The authors concluded that those findings needed confirmation in phase 3 trials. In 2013 The Lancet also published an expression of concern about the paper.
After that the record thins. The registered trials on ClinicalTrials.gov numbered 13 on November 16, 2026. Eleven were completed and two were withdrawn before enrolling anyone. None is a phase 3 obesity trial, and none is recruiting. A 140-person open-label study of long-term use finished in 2008, and its record has no posted results.
Saniona says a partner company completed a phase 3 program in people with obesity. Those results are not on ClinicalTrials.gov, and a PubMed search of article titles on November 16, 2026 found no report of them. A combination of tesofensine with the beta blocker metoprolol was also tested in 21 adults with hypothalamic obesity, a rare condition, for 24 weeks (Eur J Endocrinol, 2022). The developer says its later trials of that combination were paused for lack of funding.
Semaglutide's record is of a different size, and it belongs to the brand drug. The Wegovy label reports a 68-week trial of 1,961 adults in which mean weight loss was 14.9% on Wegovy 2.4 mg and 2.4% on placebo. That trial used brand Wegovy, not compounded semaglutide. None of the 13 registered tesofensine trials used semaglutide as a comparator.
Twenty-four weeks in 203 people is a beginning.
Tesofensine FDA approval & legal status
On tesofensine FDA approval, the answer is short: there is none. A search of FDA's Drugs@FDA data on November 16, 2026 returned no tesofensine product. Federal law requires new drugs to be shown safe and effective for their intended use before they are marketed (FDA).
Compounding does not fill the gap. In a warning letter dated December 8, 2025, FDA named tesofensine among ingredients that are ineligible for use in human drug compounding under section 503A, the part of federal law that covers pharmacy compounding (FDA warning letter, 2025). Tesofensine is also absent from FDA's list of bulk substances for compounding (21 CFR 216.23).
Nor is tesofensine a scheduled drug. It does not appear on the Drug Enforcement Administration's alphabetical list of controlled substances dated November 12, 2026 (DEA). Unscheduled is not the same as approved.
Outside the United States, tesofensine is not approved in Mexico either. Its developer, Saniona, reported in November 2024 that Mexico's regulator, COFEPRIS, had withheld approval of its partner's application, and in February 2025 that the application was being revised and resubmitted. Saniona's pipeline page, read November 16, 2026, lists no approval. A 2026 paper from anti-doping researchers at the German Sport University Cologne adds that tesofensine has been marketed online as a dietary supplement, and that the World Anti-Doping Agency prohibits it in competition as a stimulant (Drug Test Anal, 2026).
For the medicines that have cleared review, see the FDA-approved weight loss medications guide from NIDDK. Related: a second drug that draws searches ahead of any approval is retatrutide still in trials.
Cost & how each is sourced
With no approved product, tesofensine has no pharmacy list price, no label and no labeled dose. Anything sold under the name has not been through FDA review, and the Cologne study used a product sold as a dietary supplement. No price is compared here, because there is no approved tesofensine product to price.
Semaglutide shots reach you through a prescription. Brand Wegovy is the FDA-approved form for weight management. Compounded semaglutide is not FDA approved, which means FDA does not verify its safety, effectiveness or quality before it is marketed (FDA).
In Harbor's semaglutide program, semaglutide is listed from $89 a month (compounded, not FDA approved), with medication, clinician care and check-ins in one price. No insurance is required, and HSA and FSA cards are accepted. The program page describes that price as flat as your dose goes up.
| Attribute | Semaglutide shots | Tesofensine |
|---|---|---|
| What it is | A peptide that acts on the GLP-1 receptor | A small molecule, not a peptide |
| How it is taken | Injection under the skin, once a week | By mouth, once a day in trials |
| FDA approval of the drug | Approved in 2017, and for weight management in 2021 as brand Wegovy Wegovy approved | Never approved for any use |
| Compounded product | Not FDA approved | Ineligible for pharmacy compounding, per FDA |
| Largest published weight trial | Brand Wegovy: 1,961 adults for 68 weeks | Phase 2: 203 adults for 24 weeks |
| Dose | Set by your clinician Clinician-set | No approved label, so no labeled dose |
| Route to a prescription | A licensed clinician reviews you first Clinician review | No approved product to prescribe |
| Through Harbor | From $89 a month (compounded, not FDA approved), after a physician review | Not an Harbor program |
Scroll the table sideways to see both columns →
Who should choose compounded semaglutide instead
Harbor compounded semaglutide is built for adults seeking medically supervised GLP-1 weight loss, typically those with a BMI of 27 or higher. It is a once-weekly semaglutide injection you give yourself at home, and a board-certified physician reviews your health history and decides whether treatment is appropriate for you. Compounded semaglutide is not FDA approved.
Semaglutide shots may suit you when:
- You have weight to lose and want a medically guided approach
- You prefer steady, sustainable progress over a crash diet
- You want clinician support and aftercare along with the prescription
- You are ready for a simple, once-weekly routine at home
If tesofensine appealed to you because it is a tablet, mention that in your review. Harbor's semaglutide program is one injection a week at home rather than a pill every day, and your clinician can walk you through the routine before anything ships.
The medication arrives as a prescribed vial with U-100 insulin syringes, according to the program FAQ. Background reading on how that works: compounded weight loss medications explained.
Use the review to list everything you take, including anything bought online. One member, Leah Nadel, wrote in an August 20, 2026 Trustpilot review that she was "happy that a medical provider is available to answer any questions about my medical health that might interfere with the medication."
Eligibility comes first
The GLP-1 program is not open to people who are pregnant, breastfeeding or planning pregnancy, or to anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. If a clinician does not approve treatment, the payment is refunded in full. For anything else, message your Harbor clinician.
Bottom line on tesofensine for weight loss
Tesofensine for weight loss is still a research story: one published 24-week phase 2 trial in obesity, no FDA approval for any use, and an FDA letter that rules it out for pharmacy compounding.
Semaglutide is further along. The drug is FDA approved as Wegovy for weight management, and a licensed clinician can review you for semaglutide today. Compounded semaglutide, the form in Harbor's program, is not FDA approved.
That program is designed to end. It starts with a weekly shot at home and licensed clinicians available 24/7 for medical questions through the patient portal, and it finishes with a clinician-guided taper and registered-dietitian aftercare when you reach your goal.
The online quiz takes about 90 seconds and is the first step toward a physician review. If semaglutide is not the right fit, it is not prescribed.
Medical disclaimer
This article is for general education and is not medical advice. It is not a substitute for evaluation, diagnosis, or treatment by a licensed clinician. Talk with a qualified clinician about your individual situation.
Compounded medications
Harbor is a technology platform. Medical evaluations are conducted by independent, licensed healthcare providers who determine whether treatment is appropriate. Compounded medications are not FDA approved and are not reviewed by the FDA for safety or effectiveness.
Frequently asked questions
There is no one-word answer. Tesofensine is not on the Drug Enforcement Administration's list of controlled substances dated November 12, 2026. It is also not FDA approved for any use, and FDA wrote in December 2025 that it is ineligible for pharmacy compounding under section 503A. That leaves no FDA-approved tesofensine product for a clinician to prescribe.
Not on the evidence. Tesofensine vs tirzepatide sets one published 24-week phase 2 trial of 203 people against a drug FDA approved in 2023, as Zepbound, for chronic weight management. The Zepbound label reports a 72-week trial of 2,539 adults. No registered tesofensine trial used tirzepatide as a comparator. Compounded tirzepatide is not FDA approved.
Published tesofensine results come mainly from one phase 2 trial of 203 adults. Over 24 weeks, mean weight loss was 4.5% to 10.6% greater than diet and placebo, depending on the dose. Its authors called for phase 3 confirmation, The Lancet later published an expression of concern about the paper, and no phase 3 obesity trial is registered on ClinicalTrials.gov. A trial average is not a personal forecast.
Sources
- Astrup A, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9653):1906-1913.
- The Lancet Editors. Expression of concern: effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients. Lancet. 2013;381(9873):1167.
- Sjodin A, et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int J Obes (Lond). 2010;34(11):1634-1643.
- Huynh K, et al. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. Eur J Endocrinol. 2022;186(6):687-700.
- Krug O, Thomas A, Thevis M. Investigations into the metabolism and elimination of tesofensine in human urine. Drug Test Anal. 2026;18(9):1163-1173.
- ClinicalTrials.gov. Registered studies for the search term tesofensine (13 studies, searched November 16, 2026).
- ClinicalTrials.gov. NCT00148512: efficacy and safety study of tesofensine (NS 2330) in Parkinson's disease, Boehringer Ingelheim, started March 2003.
- ClinicalTrials.gov. NCT00153010: three doses of NS 2330 in mild to moderate dementia of the Alzheimer's type, Boehringer Ingelheim, started February 2003.
- ClinicalTrials.gov. NCT00481104: evaluation of long term safety of tesofensine in patients with obesity, NeuroSearch A/S, completed November 2008.
- DailyMed. Wegovy (semaglutide) injection and tablets, prescribing information (revised June 2026).
- DailyMed. Zepbound (tirzepatide) injection, prescribing information (revised August 2026).
- U.S. Food and Drug Administration. Drugs@FDA: Wegovy, NDA 215256, approved June 4, 2021.
- U.S. Food and Drug Administration. Drugs@FDA: Zepbound, NDA 217806, approved November 8, 2023.
- U.S. Food and Drug Administration. Warning letter to a bulk drug ingredient distributor, MARCS-CMS 716152 (December 8, 2025).
- U.S. Food and Drug Administration. Unapproved drugs (content current as of May 9, 2024).
- U.S. Food and Drug Administration. Compounding and the FDA: questions and answers (content current as of September 16, 2025).
- 21 CFR 216.23. Bulk drug substances that can be used to compound drug products in accordance with section 503A. Electronic Code of Federal Regulations.
- Drug Enforcement Administration, Diversion Control Division. Controlled substances, alphabetical order (November 12, 2026).
- National Center for Biotechnology Information. PubChem compound summary for CID 11370864, tesofensine.
- National Human Genome Research Institute. Talking glossary of genomic and genetic terms: peptide.







